MDI Administration Protocol for Mechanically Ventilated Patients
For patients on mechanical ventilation, administer bronchodilators via MDI with a spacer device connected to the inspiratory limb of the ventilator circuit, using 2 puffs every 2-4 hours of short-acting beta-agonists (such as albuterol) and/or ipratropium, with actuation timed at the onset of lung inflation. 1
Device Setup and Circuit Configuration
Connect the MDI to a spacer or valved holding chamber positioned in the inspiratory limb of the ventilator circuit, ideally within 30 cm of the Y-piece. 2 The spacer significantly improves drug delivery compared to direct MDI actuation into the circuit. 3, 4
- Chamber-style spacer devices produce greater respirable volume than in-line or elbow-style adapters 4
- The spacer should remain connected only during medication administration, then removed and cleaned between uses 2
- Lung deposition ranges from 1.5-6% in ventilated patients compared to 10-15% in spontaneously breathing patients 2, 3
Timing and Technique
Actuate the MDI at the precise onset of the ventilator's inspiratory cycle to maximize drug delivery to the lower respiratory tract. 2, 5
- Synchronize actuation with the beginning of mechanical inspiration 5
- Temporarily disconnect humidification for a few minutes before and throughout medication administration 2, 5
- Humidity reduces aerosol delivery by approximately 50% (from 28-39% to 15-20% of nominal dose) 5
Dosing Protocol
Administer 2 puffs every 2-4 hours for maintenance bronchodilation in ventilated COPD patients. 1 However, due to reduced lung deposition during mechanical ventilation, higher doses may be required compared to spontaneously breathing patients.
- As few as 4 puffs of sympathomimetic aerosol can achieve significant bronchodilation when technique is optimized 3
- For acute exacerbations requiring intensive care, consider increasing frequency based on clinical response 1
- Each standard albuterol MDI puff delivers 90 mcg 6
Ventilator Settings That Optimize Delivery
Aerosol delivery correlates directly with inspiratory time and duty cycle (inspiratory time/total respiratory cycle time). 5
- Longer inspiratory times improve drug deposition (linear correlation r > 0.91) 5
- CPAP mode with spontaneous breathing achieves higher delivery (39%) than controlled modes (28-31%) 5
- Tidal volumes of 700-800 mL optimize delivery in adults 5
- Lower respiratory rates (10 breaths/min) allow adequate inspiratory time 5
Critical Pitfalls to Avoid
Never leave the spacer permanently connected in-line, as this increases contamination risk and reduces reliability. 2 Remove and clean the device between treatments.
Do not actuate multiple puffs rapidly in succession without allowing the ventilator to deliver each dose. Space actuations to coincide with separate mechanical breaths.
Avoid administering MDIs through active humidification systems without temporarily disconnecting them, as this dramatically reduces drug delivery. 2, 5
Do not assume nebulizers are superior for ventilated patients—properly administered MDIs with spacers achieve comparable clinical effects with less contamination risk and lower cost. 3, 7
Alternative Delivery Methods
If MDI administration is ineffective or unavailable, consider:
- Jet nebulizer connected to the inspiratory limb with high gas flow, diluting medication to fill nebulizer to capacity (aerosol deposition 1.2-3.0% in adults) 2
- Ultrasonic nebulizer connected to inspiratory limb (aerosol deposition approximately 1.3% in infants) 2
- Both require temporary discontinuation of humidification during treatment 2
Monitoring Response
Assess bronchodilator response through:
- Peak inspiratory pressure reduction 3
- Improved compliance 3
- Reduced work of breathing 3
- Clinical examination findings 1
The reduced lung deposition in ventilated patients (4.9-39.2% of nominal dose depending on technique) means clinical response, not fixed dosing, should guide therapy adjustments. 5